Advertisement
Advertisement

Research Alert: Study Casts Doubt on "Shock and Kill" Cure Strategy

Is Protease Inhibitor Monotherapy Sufficient to Keep HIV Under Control in the Brain?

November 1, 2012

 < Prev  |  1  |  2  |  3  |  4 

References

  1. Spudich S, Gisslén M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. Journal of Infectious Diseases. 2011 Sep 1;204(5):753-60.
  2. Gisslén M, Fuchs D, Hagberg L, et al. Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scandinavian Journal of Infectious Diseases. 2012; in press.
  3. Mellgren A, Price RW, Hagberg L, et al. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology. 2007 Oct 9;69(15):1536-41.
  4. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Current Opinion in Infectious Diseases. 2012 Feb;25(1):4-9.
  5. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010 Nov 16;75(20):1786-93.
  6. Bloomfield SM, McKinney J, Smith L, et al. Reliability of S100B in predicting severity of central nervous system injury. Neurocritical Care. 2007;6(2):121-38.
  7. Du Pasquier RA, Jilek S, Kalubi M, et al. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS. 2012; in press.
  8. Vivithanaporn P, Nelles K, DeBlock L, et al. Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Journal of the Neurological Sciences. 2012 Jan 15;312(1-2):45-51.
  9. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of Neurovirology. 2011 Feb;17(1):3-16.
  10. Cruse B, Cysique LA, Markus R et al. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Journal of Neurovirology. 2012 Aug;18(4):264-76.
  11. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012 Sep 10;26(14):1765-74.
  12. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Medicine. 2012; in  press.
  13. Nakamoto BK, Jahanshad N, McMurtray A, et al. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. Journal of Neurovirology. 2012 Aug;18(4):303-12.
  14. Towgood KJ, Pitkanen M, Kulasegaram R, et al. Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Human Brain Mapping. 2012; in press.
  15. Ances BM, Ortega M, Vaida F, et al. Independent effects of HIV, aging, and HAART on brain volumetric measures. Journal of Acquired Immune Deficiency Syndromes. 2012 Apr 15;59(5):469-77.
  16. Kallianpur KJ, Kirk GR, Sailasuta N, et al. Regional cortical thinning associated with detectable levels of HIV DNA. Cerebral Cortex. 2012 Sep;22(9):2065-75.
  17. Lane TA, Moore DM, Batchelor J, et al. Facial Emotional Processing in HIV Infection: relation to neurocognitive and neuropsychiatric Status. Neuropsychology. 2012; in press.
  18. Jin J, Lam L, Sadic E, et al. HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND. American Journal of Translational Research. 2012;4(3):302-15.
  19. Morgan EE, Woods SP, Smith C, et al. Lower Cognitive Reserve Among Individuals with Syndromic HIV-Associated Neurocognitive Disorders (HAND). AIDS and Behavior. 2012; in press.
  20. Soontornniyomkij V, Moore DJ, Gouaux B, et al. Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS. 2012; in press.
  21. McCombe J, Vivithanaporn P, Gill M, et al. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Medicine. 2012; in press.
  22. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes. 2012 Jul 1;60(3):234-43.
  23. Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. Journal of Infectious Diseases. 2010 Jul 1;202(1):161-70.
  24. Dang Q, Whitted S, Goeken RM, et al. Development of neurological disease is associated with increased immune activation in SIV infected macaques. Journal of Virology. 2012; in press.
  25. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003.
  26. Estébanez M, Arribas JR. Protease inhibitor monotherapy: what is its role? Current HIV/AIDS Reports. 2012 Jun; 9(2):179-85.
  27. Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. Journal of Acquired Immune Deficiency Syndromes. 2007 Apr 1;44(4):417-22.
  28. Stebbing J, Nathan B, Jones R, et al. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS. 2007 Aug 20;21(13):1826-8.
 < Prev  |  1  |  2  |  3  |  4 



This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication CATIE News. Visit CATIE's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement